Impact of Chemotherapy on Hypercalcemia in Breast and Lung Cancer Patients

Hassan, Bassam Abdul Rasool; Yusoff, Zuraidah Binti Mohd; Hassali, Mohamed Azmi; Othman, Saad Bin; Weiderpass, Elisabete

추천

검색

자료유형: 학술저널

저자정보: Hassan, Bassam Abdul Rasool (Clinical Pharmacy Discipline, School of Pharmaceutical Sciences, University Sains Malaysia) Yusoff, Zuraidah Binti Mohd (Clinical Pharmacy Discipline, School of Pharmaceutical Sciences, University Sains Malaysia) Hassali, Mohamed Azmi (Discipline of Social and Administrative Pharmacy, School of Pharmaceutical Sciences, University Sains Malaysia) Othman, Saad Bin (Clinical Pharmacy Discipline, School of Pharmaceutical Sciences, University Sains Malaysia) Weiderpass, Elisabete (Department of Epidemiology and Biostatistics, Karolinksa Institutet)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제9호

발행연도: 2012.1

수록면: 4,373 - 4,378 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Introduction: Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases. However, hypercalcemia may occur in patients with or without bone metastases. The present study aimed to describe the effect of chemotherapy treatment, regimens and doses on calcium levels among breast and lung cancer patients with hypercalcemia. Methods: We carried a review of medical records of breast and lung cancer patients hospitalized in years 2003 and 2009 at Penang General Hospital, a public tertiary care center in Penang Island, north of Malaysia. Patients with hypercalcemia (defined as a calcium level above 10.5 mg/dl) at the time of cancer diagnosis or during cancer treatment had their medical history abstracted, including presence of metastasis, chemotherapy types and doses, calcium levels throughout cancer treatment, and other co-morbidity. The mean calcium levels at first hospitalization before chemotherapy were compared with calcium levels at the end of or at the latest chemotherapy treatment. Statistical analysis was conducted using the Chi-square test for categorical data, logistic regression test for categorical variables, and Spearman correlation test, linear regression and the paired sample t tests for continuous data. Results: Of a total 1,023 of breast cancer and 814 lung cancer patients identified, 292 had hypercalcemia at first hospitalization or during cancer treatment (174 breast and 118 lung cancer patients). About a quarter of these patients had advanced stage cancers: 26.4% had mild hypercalcemia (10.5-11.9 mg/dl), 55.5% had moderate (12-12.9 mg/dl), and 18.2% severe hypercalcemia (13-13.9; 14-16 mg/dl). Chemotherapy lowered calcium levels significantly both in breast and lung cancer patients with hypercalcemia; in particular with chemotherapy type 5-flurouracil+epirubicin+cyclophosphamide (FEC) for breast cancer, and gemcitabine+cisplatin in lung cancer. Conclusion: Chemotherapy decreases calcium levels in breast and lung cancer cases with hypercalcemia at cancer diagnosis, probably by reducing PTHrP levels.

#Hypercalcemia #PTHrP #chemotherapy type #breast cancer #lung cancer

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요